Erasca, Inc. — Fiscal 2022 Form 10-K Summary
Business context and reporting period
Erasca is a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers. This Form 10-K covers the fiscal year ended December 31, 2022, and was filed March 23, 2023. The company has no approved products and generated no revenue.
The pipeline comprised 12 disclosed programs, including five clinical-stage programs: naporafenib, ERAS-007, ERAS-601, ERAS-801 and ERAS-3490. The company relies on third parties for clinical research, manufacturing, packaging and distribution.
Financial performance and liquidity
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $112.5 million | $73.9 million | +$38.5 million |
| In-process R&D expense | $102.0 million | $10.8 million | +$91.2 million |
| General and administrative expense | $33.0 million | $22.6 million | +$10.4 million |
| Total operating expenses | $247.5 million | $124.9 million | +$122.6 million |
| Net loss | $242.8 million | $122.8 million | Loss increased by $120.0 million |
| Net loss per share | $1.99 | $1.85 | Loss per share increased |
| Cash used in operating activities | $103.3 million | $79.6 million | Use increased by $23.7 million |
| Cash, cash equivalents and marketable securities | $435.6 million | Not clearly stated as a comparable combined figure in the filing summary | — |
At December 31, 2022, cash and cash equivalents were $284.2 million and short-term marketable securities were $151.4 million. Total assets were $514.9 million, total liabilities were $103.1 million, and stockholders’ equity was $411.9 million. The company had no funded debt disclosed; liabilities primarily consisted of accounts payable, accrued expenses and operating lease liabilities.
Operating cash use was driven by the net loss, clinical and preclinical development spending, personnel costs and facility expansion. Investing cash use was $71.1 million, including purchases of marketable securities, property and equipment, a $2.0 million investment in Affini-T Therapeutics and a $2.0 million in-process R&D payment. Financing cash inflow was $98.1 million, principally from the December 2022 common-stock offering.
Management stated that existing cash, cash equivalents and marketable securities were expected to fund operations into the second half of 2025, subject to assumptions regarding development timing, costs and financing needs. The filing also states that the company will require substantial additional capital and has no committed external source of funds.
Material changes versus the prior comparable period
- R&D expense increased 52% to $112.5 million, reflecting greater clinical, preclinical and discovery activity, higher headcount, stock-based compensation and facility costs.
- In-process R&D expense increased substantially because of the naporafenib license from Novartis. Erasca recorded a $20.0 million upfront cash payment and issued 12,307,692 shares valued at approximately $80.0 million. It also paid a $2.0 million development milestone to Katmai.
- Net loss approximately doubled to $242.8 million, while operating cash use increased to $103.3 million.
- The company completed a December 2022 underwritten offering of 15,384,616 shares at $6.50 per share, generating $94.9 million of net proceeds.
- The company entered into a $200 million at-the-market equity facility in August 2022; no shares had been sold under the facility by December 31, 2022.
- Cash, cash equivalents and marketable securities declined during the year despite the equity offering, reflecting operating and investing cash use.
- The company expanded its facilities, moved into new San Diego and South San Francisco locations and reported $87.4 million of future operating lease payments at year-end.
Pipeline, outlook and management commentary
- Naporafenib: In-licensed from Novartis in December 2022. Management planned a Phase 1b SEACRAFT-1 trial in RAS Q61X solid tumors in the second half of 2023 and a potentially pivotal Phase 3 SEACRAFT-2 trial in NRAS-mutated melanoma in the first half of 2024.
- ERAS-007 and ERAS-601: The company continued HERKULES and FLAGSHP-1 development programs and began evaluating the ERAS-007/ERAS-601 MAPKlamp combination; the first patient in the combination study was dosed in December 2022.
- ERAS-801: The Phase 1 THUNDERBBOLT-1 trial in recurrent glioblastoma was ongoing, with initial data expected in the second half of 2023.
- ERAS-3490: The FDA cleared the IND in December 2022 for the CNS-penetrant KRAS G12C inhibitor. The company planned the AURORAS-1 Phase 1 study and expected a data readout in 2024.
- Preliminary clinical data were encouraging but early. Examples included responses with naporafenib plus trametinib in NRAS-mutated melanoma, and isolated responses with ERAS-007 and ERAS-601. The filing cautions that preliminary and interim data may change as additional patients and follow-up become available.
- Management expects expenses and operating losses to increase as trials advance, additional programs enter clinical development, manufacturing capacity is expanded and commercialization capabilities are developed.
Risks, contingencies and unusual items
- The company has a limited operating history, a $481.0 million accumulated deficit and expects significant losses for the foreseeable future. It may never generate product revenue or achieve profitability.
- Clinical development remains early and uncertain. Erasca has not completed a pivotal trial or obtained regulatory approval for any product candidate.
- Combination therapies may create overlapping or unexpected toxicities. Reported class-related risks include skin, gastrointestinal, liver, hematologic and ophthalmic adverse events.
- The company depends on third-party CROs, clinical sites and manufacturers and lacks owned manufacturing facilities or fully redundant supply arrangements.
- License agreements contain contingent regulatory and sales milestones and royalty obligations. The Novartis agreement includes up to $80.0 million of regulatory milestones, up to $200.0 million of sales milestones and low-single-digit royalties.
- Future financing may dilute existing holders or require the company to relinquish rights. The filing identifies equity, debt, collaboration and licensing transactions as potential funding sources.
- Marketable securities included $1.0 million of unrealized losses at year-end, primarily attributable to market interest-rate movements. The company stated that it did not expect credit losses and did not intend or expect to sell the affected securities before recovery.
- Operating lease liabilities totaled approximately $55.1 million after discounting, with undiscounted future lease payments of $87.4 million.
- The company reported no material legal proceedings and no unresolved SEC staff comments.
- Stock-based compensation was $20.1 million in 2022, up from $8.3 million in 2021, and unrecognized compensation cost for unvested options was $52.8 million at year-end.
- The company recorded a $2.2 million employee retention credit in 2022, which reduced research and development and general and administrative expenses.
Important facts for investors to verify
- Whether naporafenib’s planned SEACRAFT trials began on schedule and whether regulators accepted the proposed pivotal-trial design.
- Updated efficacy, durability, safety and dosing data for naporafenib, ERAS-007, ERAS-601, ERAS-801 and ERAS-3490, distinguishing confirmed from unconfirmed responses.
- The pace of cash burn and whether the stated runway into the second half of 2025 remains accurate after incorporating trial expansion, milestone payments and lease obligations.
- Any use of the $200 million at-the-market facility or other equity or debt financing, including resulting dilution.
- Potential regulatory, development and sales milestone obligations under the Novartis, Asana, NiKang, Katmai, LifeArc and UCSF agreements.
- Manufacturing readiness, supply-chain redundancy and the ability of third-party manufacturers to support larger or pivotal trials.
- Changes in clinical-trial enrollment, competitive programs, regulatory requirements and reimbursement assumptions that could alter the company’s development strategy or addressable markets.